Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence

Muhammad Mujtaba, Asif A. Sharfuddin, Benita L. Book, William C. Goggins, Ali A. Khalil, Dennis P. Mishler, Johnathan A. Fridell, Muhammad S. Yaqub, Tim E. Taber

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Post-kidney transplant recurrence of focal segmental glomerulosclerosis (FSGS) is a major problem. AT1R is expressed on podocyte; its expression is elevated in the proteinuric state. Using an ELISA, we tested pre-transplant sera of 28 patients with history of idiopathic FSGS for anti-AT1R levels and serum soluble urokinase-type plasminogen activator receptor (suPAR) as a biomarker for risk of recurrence of FSGS. Sera from 11 patients with polycystic kidney disease (PKD) were used as controls. Twelve patients had biopsy proven post-transplant FSGS recurrence at 1.5 months. No difference was found in the pre-transplant suPAR levels of FSGS patients (5993 ± 2292 pg/mL) vs. PKD (7334 ± 4538 pg/mL) (p = 0.23). Serum suPAR levels in patients with FSGS recurrence (5786 ± 1899 pg/mL) vs. no FSGS recurrence (6149 ± 2598 pg/mL) (p = 0.69) were not different. Anti-AT1R levels in patients with FSGS were 12.66 ± 11.85 U/mL vs. 8.69 ± 6.52 U/mL in PKD (p = 0.32); however, a difference was found in patients with and without FSGS recurrence 20.41 ± 14.36 U/mL 6.84 ± 4.181 U/mL, respectively (p < 0.01). Area under curve for suPAR and anti-AT1R to predict post-transplant FSGS recurrence was 0.51 and 0.84, respectively. Pre-transplant anti-AT1R levels appear to be a helpful biomarker in identifying patients at high risk of post-transplant FSGS recurrence.

Original languageEnglish (US)
Pages (from-to)606-611
Number of pages6
JournalClinical Transplantation
Volume29
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Focal Segmental Glomerulosclerosis
Angiotensin Type 1 Receptor
Transplants
Recurrence
Antibodies
Urokinase Plasminogen Activator Receptors
Polycystic Kidney Diseases
Serum
Biomarkers
Podocytes
Area Under Curve
Enzyme-Linked Immunosorbent Assay

Keywords

  • Anti-AT1R
  • Focal segmental glomerulosclerosis
  • Recurrence
  • Transplant

ASJC Scopus subject areas

  • Transplantation

Cite this

Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence. / Mujtaba, Muhammad; Sharfuddin, Asif A.; Book, Benita L.; Goggins, William C.; Khalil, Ali A.; Mishler, Dennis P.; Fridell, Johnathan A.; Yaqub, Muhammad S.; Taber, Tim E.

In: Clinical Transplantation, Vol. 29, No. 7, 01.07.2015, p. 606-611.

Research output: Contribution to journalArticle

Mujtaba, M, Sharfuddin, AA, Book, BL, Goggins, WC, Khalil, AA, Mishler, DP, Fridell, JA, Yaqub, MS & Taber, TE 2015, 'Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence', Clinical Transplantation, vol. 29, no. 7, pp. 606-611. https://doi.org/10.1111/ctr.12562
Mujtaba, Muhammad ; Sharfuddin, Asif A. ; Book, Benita L. ; Goggins, William C. ; Khalil, Ali A. ; Mishler, Dennis P. ; Fridell, Johnathan A. ; Yaqub, Muhammad S. ; Taber, Tim E. / Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence. In: Clinical Transplantation. 2015 ; Vol. 29, No. 7. pp. 606-611.
@article{5bc1cc503255451aa906666a19935f0b,
title = "Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence",
abstract = "Post-kidney transplant recurrence of focal segmental glomerulosclerosis (FSGS) is a major problem. AT1R is expressed on podocyte; its expression is elevated in the proteinuric state. Using an ELISA, we tested pre-transplant sera of 28 patients with history of idiopathic FSGS for anti-AT1R levels and serum soluble urokinase-type plasminogen activator receptor (suPAR) as a biomarker for risk of recurrence of FSGS. Sera from 11 patients with polycystic kidney disease (PKD) were used as controls. Twelve patients had biopsy proven post-transplant FSGS recurrence at 1.5 months. No difference was found in the pre-transplant suPAR levels of FSGS patients (5993 ± 2292 pg/mL) vs. PKD (7334 ± 4538 pg/mL) (p = 0.23). Serum suPAR levels in patients with FSGS recurrence (5786 ± 1899 pg/mL) vs. no FSGS recurrence (6149 ± 2598 pg/mL) (p = 0.69) were not different. Anti-AT1R levels in patients with FSGS were 12.66 ± 11.85 U/mL vs. 8.69 ± 6.52 U/mL in PKD (p = 0.32); however, a difference was found in patients with and without FSGS recurrence 20.41 ± 14.36 U/mL 6.84 ± 4.181 U/mL, respectively (p < 0.01). Area under curve for suPAR and anti-AT1R to predict post-transplant FSGS recurrence was 0.51 and 0.84, respectively. Pre-transplant anti-AT1R levels appear to be a helpful biomarker in identifying patients at high risk of post-transplant FSGS recurrence.",
keywords = "Anti-AT1R, Focal segmental glomerulosclerosis, Recurrence, Transplant",
author = "Muhammad Mujtaba and Sharfuddin, {Asif A.} and Book, {Benita L.} and Goggins, {William C.} and Khalil, {Ali A.} and Mishler, {Dennis P.} and Fridell, {Johnathan A.} and Yaqub, {Muhammad S.} and Taber, {Tim E.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1111/ctr.12562",
language = "English (US)",
volume = "29",
pages = "606--611",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence

AU - Mujtaba, Muhammad

AU - Sharfuddin, Asif A.

AU - Book, Benita L.

AU - Goggins, William C.

AU - Khalil, Ali A.

AU - Mishler, Dennis P.

AU - Fridell, Johnathan A.

AU - Yaqub, Muhammad S.

AU - Taber, Tim E.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Post-kidney transplant recurrence of focal segmental glomerulosclerosis (FSGS) is a major problem. AT1R is expressed on podocyte; its expression is elevated in the proteinuric state. Using an ELISA, we tested pre-transplant sera of 28 patients with history of idiopathic FSGS for anti-AT1R levels and serum soluble urokinase-type plasminogen activator receptor (suPAR) as a biomarker for risk of recurrence of FSGS. Sera from 11 patients with polycystic kidney disease (PKD) were used as controls. Twelve patients had biopsy proven post-transplant FSGS recurrence at 1.5 months. No difference was found in the pre-transplant suPAR levels of FSGS patients (5993 ± 2292 pg/mL) vs. PKD (7334 ± 4538 pg/mL) (p = 0.23). Serum suPAR levels in patients with FSGS recurrence (5786 ± 1899 pg/mL) vs. no FSGS recurrence (6149 ± 2598 pg/mL) (p = 0.69) were not different. Anti-AT1R levels in patients with FSGS were 12.66 ± 11.85 U/mL vs. 8.69 ± 6.52 U/mL in PKD (p = 0.32); however, a difference was found in patients with and without FSGS recurrence 20.41 ± 14.36 U/mL 6.84 ± 4.181 U/mL, respectively (p < 0.01). Area under curve for suPAR and anti-AT1R to predict post-transplant FSGS recurrence was 0.51 and 0.84, respectively. Pre-transplant anti-AT1R levels appear to be a helpful biomarker in identifying patients at high risk of post-transplant FSGS recurrence.

AB - Post-kidney transplant recurrence of focal segmental glomerulosclerosis (FSGS) is a major problem. AT1R is expressed on podocyte; its expression is elevated in the proteinuric state. Using an ELISA, we tested pre-transplant sera of 28 patients with history of idiopathic FSGS for anti-AT1R levels and serum soluble urokinase-type plasminogen activator receptor (suPAR) as a biomarker for risk of recurrence of FSGS. Sera from 11 patients with polycystic kidney disease (PKD) were used as controls. Twelve patients had biopsy proven post-transplant FSGS recurrence at 1.5 months. No difference was found in the pre-transplant suPAR levels of FSGS patients (5993 ± 2292 pg/mL) vs. PKD (7334 ± 4538 pg/mL) (p = 0.23). Serum suPAR levels in patients with FSGS recurrence (5786 ± 1899 pg/mL) vs. no FSGS recurrence (6149 ± 2598 pg/mL) (p = 0.69) were not different. Anti-AT1R levels in patients with FSGS were 12.66 ± 11.85 U/mL vs. 8.69 ± 6.52 U/mL in PKD (p = 0.32); however, a difference was found in patients with and without FSGS recurrence 20.41 ± 14.36 U/mL 6.84 ± 4.181 U/mL, respectively (p < 0.01). Area under curve for suPAR and anti-AT1R to predict post-transplant FSGS recurrence was 0.51 and 0.84, respectively. Pre-transplant anti-AT1R levels appear to be a helpful biomarker in identifying patients at high risk of post-transplant FSGS recurrence.

KW - Anti-AT1R

KW - Focal segmental glomerulosclerosis

KW - Recurrence

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=84937145935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937145935&partnerID=8YFLogxK

U2 - 10.1111/ctr.12562

DO - 10.1111/ctr.12562

M3 - Article

VL - 29

SP - 606

EP - 611

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 7

ER -